Short answer
Altimmune, Inc. (ALT) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$23M
- −3.1% YoY · −1.2% QoQ
- EPS (diluted)
- −$0.11
- +59.3% YoY · +38.9% QoQ
Source: XBRL data from the Altimmune, Inc. (ALT) Q2 2026 10-Q on SEC EDGAR. USD.
Altimmune, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 vs $5 thousand, down 100% YoY
- Net loss $22.825M vs $22.146M; operating loss $26.229M vs $22.922M
- ALD R&D $4.604M, up 199%; MASH R&D $3.795M, down 30%
- Cash, equivalents, restricted cash and short-term investments $326.3M; long-term investments $192.3M
- Operating cash use $45.163M vs $36.190M; April offering generated $211.1M net proceeds
Risk Factors
- No material changes from 10-K risk factors filed March 6, 2026
- Carried-forward risks remain the company’s most significant disclosed risk factors
- No newly triggered regulatory, legal, operational, competitive, or market risk identified
- No quarter-specific liquidity, debt maturity, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Altimmune, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.